^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    erlotinib

    i
    Company:
    Generic mfg.
    Drug class:
    EGFR inhibitor
    Related drugs:
    Apply
    Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NCT02194738)
    Phase N/A
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/26/2014
    Primary completion :
    09/28/2026
    Completion :
    09/28/2026
    EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4
    |
    EGFR mutation • ALK rearrangement
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)
    Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors (NCT00045201)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    06/13/2002
    Primary completion :
    09/13/2013
    Completion :
    08/22/2025
    EGFR • UGT1A1
    |
    UGT1A1*1*1
    |
    erlotinib • irinotecan
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (GO42144) (NCT04449874)
    Phase 1
    Genentech, Inc.
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    07/29/2020
    Primary completion :
    02/28/2026
    Completion :
    02/28/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • erlotinib • divarasib (RG6330) • Itovebi (inavolisib) • migoprotafib (RLY-1971)
    Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (NCT01708954)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    02/13/2013
    Primary completion :
    08/14/2015
    Completion :
    03/07/2025
    HER-2 • KRAS • BRAF • RET
    |
    KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion
    |
    erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) (NCT02193282)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    02/11/2015
    Primary completion :
    10/10/2026
    Completion :
    10/10/2026
    EGFR • ALK
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement
    |
    erlotinib
    Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (KEYNOTE E27) (NCT04956640)
    Phase 1/2
    Eli Lilly and Company
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    07/19/2021
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)
    Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (NCT03297606)
    Phase 2
    Canadian Cancer Trials Group
    Recruiting
    Last update posted :
    11/12/2024
    Initiation :
    03/23/2018
    Primary completion :
    01/31/2026
    Completion :
    01/31/2027
    BRAF
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bosulif (bosutinib) • Tukysa (tucatinib) • Torisel (temsirolimus) • Inlyta (axitinib) • Erivedge (vismodegib)
    Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib (NCT02364609)
    Phase 1
    Jonathan Riess
    Completed
    Last update posted :
    10/16/2024
    Initiation :
    09/30/2015
    Primary completion :
    04/26/2018
    Completion :
    05/01/2020
    PD-L1
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q
    |
    Keytruda (pembrolizumab) • erlotinib • Gilotrif (afatinib)
    My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (NCT02091141)
    Phase 2
    Genentech, Inc.
    Completed
    Last update posted :
    07/23/2024
    Initiation :
    04/14/2014
    Primary completion :
    05/24/2023
    Completion :
    05/24/2023
    EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO
    |
    EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • erlotinib • Zelboraf (vemurafenib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Erivedge (vismodegib)
    Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PIKACHU) (NCT04322890)
    Phase 2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/16/2020
    Primary completion :
    12/24/2026
    Completion :
    12/24/2027
    EGFR • BRAF • ALK • ROS1
    |
    EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation
    |
    cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)
    The Efficacy and Safety of IBI363 in Solid Tumors (Promise) (NCT06081907)
    Phase 1/2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    12/25/2023
    Primary completion :
    12/01/2026
    Completion :
    09/01/2028
    EGFR • HER-2 • PD-L1 • BRAF • ALK • RET • CD73 • NTRK
    |
    BRAF V600E • EGFR mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation
    |
    erlotinib • Lenvima (lenvatinib)
    Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery (NCT00254384)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/23/2024
    Initiation :
    10/05/2005
    Primary completion :
    05/21/2024
    Completion :
    05/21/2024
    EGFR
    |
    EGFR expression
    |
    cisplatin • erlotinib • docetaxel
    A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) (NCT02152631)
    Phase 3
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    04/18/2024
    Initiation :
    10/03/2014
    Primary completion :
    09/15/2017
    Completion :
    12/31/2024
    KRAS
    |
    KRAS mutation
    |
    erlotinib • Verzenio (abemaciclib)
    Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies (NCT01306045)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/09/2024
    Initiation :
    02/08/2011
    Primary completion :
    02/12/2014
    Completion :
    12/31/2024
    EGFR • BRAF
    |
    EGFR mutation
    |
    erlotinib • sunitinib • lapatinib • Koselugo (selumetinib) • MK-2206
    A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib (NCT03076164)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    04/02/2024
    Initiation :
    03/01/2017
    Primary completion :
    12/18/2020
    Completion :
    12/18/2020
    EGFR
    |
    EGFR mutation
    |
    Mekinist (trametinib) • erlotinib
    Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver (NCT02273362)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    03/26/2024
    Initiation :
    11/24/2014
    Primary completion :
    02/11/2020
    Completion :
    03/10/2022
    EGFR • EGF • PCNA
    |
    EGFR positive
    |
    erlotinib
    A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (NCT02411448)
    Phase 3
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    03/18/2024
    Initiation :
    05/06/2015
    Primary completion :
    01/23/2019
    Completion :
    12/16/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • erlotinib • gefitinib • Cyramza (ramucirumab)
    GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (NCT00878163)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    03/31/2009
    Primary completion :
    01/22/2013
    Completion :
    03/07/2025
    BCL2
    |
    erlotinib • gemcitabine • Erivedge (vismodegib) • liposomal gemcitabine (FF-10832)
    A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations (Balise) (NCT01897480)
    Phase 2
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    03/01/2024
    Initiation :
    08/28/2013
    Primary completion :
    03/14/2016
    Completion :
    12/31/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q
    |
    erlotinib • emibetuzumab (LY2875358)
    Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer (NCT03647592)
    Phase N/A
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    12/27/2023
    Initiation :
    06/01/2018
    Primary completion :
    08/31/2024
    Completion :
    12/01/2025
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Avastin (bevacizumab) • erlotinib • gefitinib
    Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2) (NCT04401059)
    Phase 4
    Tian Xie
    Recruiting
    Last update posted :
    12/27/2023
    Initiation :
    11/09/2020
    Primary completion :
    09/30/2025
    Completion :
    03/30/2026
    EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1
    |
    EGFR mutation • EGFR L858R • EGFR positive
    |
    Tagrisso (osimertinib) • erlotinib • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)
    Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers (NCT02098954)
    Phase 2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    12/27/2023
    Initiation :
    07/01/2014
    Primary completion :
    12/01/2024
    Completion :
    12/12/2025
    EGFR • BRAF
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • erlotinib • gemcitabine
    A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) (NCT02352948)
    Phase 3
    AstraZeneca
    Completed
    Last update posted :
    10/11/2023
    Initiation :
    01/13/2015
    Primary completion :
    02/09/2018
    Completion :
    08/30/2023
    PD-L1
    |
    erlotinib • Imfinzi (durvalumab) • gemcitabine • Imjudo (tremelimumab-actl) • vinorelbine tartrate
    Brazilian Lung Immunotherapy Study (BLISS) (NCT05081674)
    Phase 2
    Hospital Israelita Albert Einstein
    Completed
    Last update posted :
    10/11/2023
    Initiation :
    01/01/2020
    Primary completion :
    06/30/2023
    Completion :
    07/30/2023
    EGFR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • erlotinib • carboplatin • docetaxel • Alecensa (alectinib)
    Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients (NCT06071013)
    Phase 2
    China Medical University Hospital
    Not yet recruiting
    Last update posted :
    10/06/2023
    Initiation :
    09/28/2023
    Primary completion :
    08/27/2026
    Completion :
    08/27/2026
    EGFR
    |
    EGFR mutation • EGFR positive
    |
    erlotinib • Gilotrif (afatinib) • gefitinib • nintedanib
    The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) (NCT04591431)
    Phase 2
    Fondazione per la Medicina Personalizzata
    Active, not recruiting
    Last update posted :
    10/03/2023
    Initiation :
    10/07/2020
    Primary completion :
    12/01/2024
    Completion :
    06/01/2025
    PD-L1 • BRAF
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • everolimus • lapatinib • Alecensa (alectinib) • Perjeta (pertuzumab) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Talzenna (talazoparib) • Piqray (alpelisib) • Retevmo (selpercatinib) • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Pemazyre (pemigatinib) • ipatasertib (RG7440) • Tepmetko (tepotinib) • itacitinib (INCB039110)
    To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT05442060)
    Phase 2
    OBI Pharma, Inc
    Recruiting
    Last update posted :
    08/07/2023
    Initiation :
    07/27/2022
    Primary completion :
    12/31/2024
    Completion :
    05/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    erlotinib • OBI-833
    MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy (NCT01068587)
    Phase 1/2
    NCIC Clinical Trials Group
    Completed
    Last update posted :
    08/04/2023
    Initiation :
    01/21/2010
    Primary completion :
    03/21/2014
    Completion :
    02/13/2015
    EGFR
    |
    EGFR expression • EGFR negative
    |
    cisplatin • erlotinib • foretinib (GSK1363089)
    A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors (M14-237) (NCT02099058)
    Phase 1
    AbbVie
    Active, not recruiting
    Last update posted :
    07/17/2023
    Initiation :
    01/15/2014
    Primary completion :
    04/24/2024
    Completion :
    04/24/2024
    MET
    |
    EGFR mutation • EGFR L858R • EGFR wild-type
    |
    Opdivo (nivolumab) • Tagrisso (osimertinib) • erlotinib • telisotuzumab vedotin (ABBV-399) • telisotuzumab (h224G11)
    A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (BRISK) (NCT05904457)
    Phase 2
    Asan Medical Center
    Recruiting
    Last update posted :
    06/14/2023
    Initiation :
    01/02/2023
    Primary completion :
    01/31/2025
    Completion :
    01/31/2026
    FH
    |
    Avastin (bevacizumab) • erlotinib • Aybintio (bevacizumab biosimilar)
    Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer (NCT02154490)
    Phase N/A
    SWOG Cancer Research Network
    Completed
    Last update posted :
    06/01/2023
    Initiation :
    07/08/2014
    Primary completion :
    04/01/2022
    Completion :
    04/15/2022
    EGFR • ALK • EML4 • TP63
    |
    EGFR mutation • ALK fusion • TTF1 negative
    |
    Opdivo (nivolumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Talzenna (talazoparib) • Imjudo (tremelimumab-actl) • fexagratinib (ABSK091) • taselisib (GDC-0032) • rilotumumab (AMG 102)
    EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas (NCT01257594)
    Phase 1
    Andrew B Lassman, MD
    Completed
    Last update posted :
    05/25/2023
    Initiation :
    01/07/2011
    Primary completion :
    11/22/2016
    Completion :
    12/31/2018
    EGFR
    |
    EGFR mutation
    |
    erlotinib
    The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib (UpSwinG) (NCT04179890)
    Phase N/A
    Boehringer Ingelheim
    Completed
    Last update posted :
    05/25/2023
    Initiation :
    12/17/2019
    Primary completion :
    07/22/2021
    Completion :
    07/22/2021
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR T790M
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib
    Study of Ixazomib and Erlotinib in Solid Tumors (NCT02942095)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    04/18/2023
    Initiation :
    03/06/2017
    Primary completion :
    12/07/2022
    Completion :
    12/07/2022
    KRAS
    |
    KRAS mutation • EGFR T790M • KRAS G12 • EGFR positive • KRAS G13 • EGFR negative
    |
    erlotinib • Ninlaro (ixazomib)
    Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy (NCT01332279)
    Phase 1
    Fox Chase Cancer Center
    Withdrawn
    Last update posted :
    04/04/2023
    Initiation :
    04/01/2011
    Primary completion :
    05/01/2011
    Completion :
    05/01/2011
    EGFR • HIF1A
    |
    EGFR amplification • HIF1A expression • AKT1 amplification
    |
    erlotinib • everolimus
    Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer (BEVERLY) (NCT02633189)
    Phase 3
    National Cancer Institute, Naples
    Active, not recruiting
    Last update posted :
    03/24/2023
    Initiation :
    04/01/2016
    Primary completion :
    12/01/2023
    Completion :
    07/01/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C
    |
    Avastin (bevacizumab) • erlotinib
    A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation (NCT01859026)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Completed
    Last update posted :
    01/19/2023
    Initiation :
    12/30/2013
    Primary completion :
    08/22/2019
    Completion :
    08/22/2019
    EGFR • KRAS
    |
    KRAS mutation • EGFR mutation
    |
    erlotinib • Mektovi (binimetinib)
    BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) (NCT01562028)
    Phase 2
    ETOP IBCSG Partners Foundation
    Completed
    Last update posted :
    08/24/2022
    Initiation :
    06/01/2012
    Primary completion :
    10/31/2018
    Completion :
    10/31/2018
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation
    |
    Avastin (bevacizumab) • erlotinib
    A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer (BGBC004) (NCT02424617)
    Phase 1/2
    BerGenBio ASA
    Completed
    Last update posted :
    08/18/2022
    Initiation :
    03/01/2015
    Primary completion :
    08/25/2021
    Completion :
    08/25/2021
    EGFR • GAS6
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib) • erlotinib • bemcentinib (BGB324)
    Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer (NCT02961374)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/26/2022
    Initiation :
    10/27/2017
    Primary completion :
    02/23/2020
    Completion :
    09/27/2021
    APC
    |
    APC mutation
    |
    erlotinib
    Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NCT00553800)
    Phase 2
    Fox Chase Cancer Center
    Completed
    Last update posted :
    07/12/2022
    Initiation :
    07/05/2007
    Primary completion :
    01/12/2011
    Completion :
    06/01/2011
    EGFR
    |
    EGFR expression
    |
    Avastin (bevacizumab) • erlotinib